Cover Image
市場調查報告書

巨噬細胞菌落刺激因子1受體:開發中產品分析

Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 366664
出版日期 內容資訊 英文 160 Pages
訂單完成後即時交付
價格
Back to Top
巨噬細胞菌落刺激因子1受體:開發中產品分析 Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) - Pipeline Review, H2 2016
出版日期: 2016年07月13日 內容資訊: 英文 160 Pages
簡介

本報告提供以巨噬細胞菌落刺激因子1受體為標的治療藥之開發平台現狀及最新更新的各開發階段比較分析,提供您附最新的新聞和發表之企業和研究機關正在開發的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

巨噬細胞菌落刺激因子1受體 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀

開發中產品概況

  • 後期階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

企業開發中的產品

大學/機關開發中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

治療藥的開發企業

  • AB Science SA
  • Amgen Inc.
  • AstraZeneca Plc
  • BCI Pharma
  • Chroma Therapeutics Limited
  • CTI BioPharma Corp.
  • Deciphera Pharmaceuticals, LLC
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Five Prime Therapeutics, Inc.
  • Ignyta, Inc.
  • Johnson & Johnson
  • Novartis AG
  • Pfizer Inc.
  • Plexxikon Inc.
  • SignalChem Lifesciences Corp
  • Transgene SA

藥物簡介

暫停中的計劃

開發中止的產品

主要消息及新聞稿

附錄

圖表

目錄
Product Code: GMDHC0386TDB

Summary

Global Markets Direct's, 'Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) - Pipeline Review, H2 2016', provides in depth analysis on Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) targeted pipeline therapeutics.

The report provides comprehensive information on the Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1)
  • The report reviews Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) Overview
  • Therapeutics Development
    • Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) - Products under Development by Stage of Development
    • Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) - Products under Development by Therapy Area
    • Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) - Products under Development by Indication
  • Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) - Pipeline Products Glance
    • Late Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) - Products under Development by Companies
  • Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) - Products under Development by Universities/Institutes
  • Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) - Therapeutics Assessment
    • Assessment by Monotherapy/Combination Products
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) - Companies Involved in Therapeutics Development
    • AB Science SA
    • Amgen Inc.
    • AstraZeneca Plc
    • BCI Pharma
    • Chroma Therapeutics Limited
    • CTI BioPharma Corp.
    • Deciphera Pharmaceuticals, LLC
    • Eli Lilly and Company
    • F. Hoffmann-La Roche Ltd.
    • Five Prime Therapeutics, Inc.
    • Ignyta, Inc.
    • Johnson & Johnson
    • Novartis AG
    • Pfizer Inc.
    • Plexxikon Inc.
    • SignalChem Lifesciences Corp
    • Transgene SA
  • Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) - Drug Profiles
    • AMG-820 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BLZ-945 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • cediranib maleate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DCC-3014 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Drug to Antagonize CSF1R for Malignant Ascites - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • emactuzumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • FPA-008 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • JNJ-28312141 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • JNJ-40346527 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LY-3022855 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • masitinib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pacritinib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pazopanib hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pazopanib hydrochloride + pembrolizumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PD-0360324 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pexidartinib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PLX-73086 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PLX-7486 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RXDX-105 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Antagonize CSF1R for Oncology and Neuroinflammation - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Antagonize FLT3 and CSF1R for AML and Inflammation - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Antagonize CSF-1 Receptor for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Antagonize CSF-1R for Inflammation - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit cFMS Kinase for Immunology and Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit FMS for Rheumatoid Arthritis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit FMS Kinase for Central Nervous System, Gastrointestinal, Immunology and Respiratory Diseases - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • sunitinib malate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TG-3003 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) - Dormant Projects
  • Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) - Discontinued Products
  • Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) - Featured News & Press Releases
    • Jul 04, 2016: Review of the conditional marketing authorization application of masitinib in amyotrophic lateral sclerosis (ALS) will follow the standard timeline of the European Medicines Agency (EMA)
    • Jun 07, 2016: Long-Term Follow Up Data For Pacritinib Presented At 2016 ASCO Annual Meeting
    • Jun 06, 2016: AB Science announces that Rapporteurs appointed by the EMA have recommended the filing of masitinib in ALS for conditional marketing authorization
    • Jun 05, 2016: Ignyta Announces Interim Data from Phase 1 Clinical Trial of Investigational Precision Medicine RXDX-105 at ASCO 2016
    • May 30, 2016: AB Science will Present Phase 3 Data in Severe Systemic Mastocytosis at the International 21St Congress of the European Hematology Association
    • May 24, 2016: Ignyta Announces RXDX-105 Phase 1 Data Presentation at the 2016 ASCO Annual Meeting
    • May 19, 2016: CTI BioPharma Announces Presentations At The American Society Of Clinical Oncology Annual Meeting
    • May 12, 2016: Five Prime Therapeutics Advances FPA008 Into Phase 2 Dose Expansion in Patients with Pigmented Villonodular Synovitis
    • May 02, 2016: AB Science has submitted to EMA the marketing authorization application for Masitinib in the Treatment of Severe Systemic Mastocytosis
    • Apr 20, 2016: Preclinical Data Presented At AACR Indicate Pacritinib Potential To Eradicate Therapy-Resistant Leukemia Stem Cells Residing In Bone Marrow Microenvironment
    • Apr 20, 2016: Deciphera's Highly-Selective Small Molecule CSF1R Immunokinase Inhibitor, DCC-3014, Demonstrates Potent Macrophage Checkpoint Inhibition as a Single Agent and In Combination with an Anti-PD1 Inhibitor
    • Apr 13, 2016: CTI BioPharma Announces Presentation on pacritinib at the American Association of Cancer Research Annual Meeting
    • Apr 11, 2016: Masitinib in Amyotrophic Lateral Sclerosis (ALS)
    • Apr 06, 2016: AB Science Will Host Live Webcast On Phase 3 Interim Analysis In ALS On 8 April 2016,
    • Apr 04, 2016: Ab Science Announces Positive Interim Results From Phase 3 Trial Of Masitinib In Amyotrophic Lateral Sclerosis
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for, H2 2016
  • Number of Products under Development by Therapy Area, H2 2016
  • Number of Products under Development by Indication, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Development by Companies, H2 2016 (Contd..2)
  • Products under Development by Companies, H2 2016 (Contd..3)
  • Products under Development by Companies, H2 2016 (Contd..4)
  • Products under Development by Companies, H2 2016 (Contd..5)
  • Products under Development by Companies, H2 2016 (Contd..6)
  • Products under Development by Companies, H2 2016 (Contd..7)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Assessment by Monotherapy/Combination Products, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Pipeline by AB Science SA, H2 2016
  • Pipeline by Amgen Inc., H2 2016
  • Pipeline by AstraZeneca Plc, H2 2016
  • Pipeline by BCI Pharma, H2 2016
  • Pipeline by Chroma Therapeutics Limited, H2 2016
  • Pipeline by CTI BioPharma Corp., H2 2016
  • Pipeline by Deciphera Pharmaceuticals, LLC, H2 2016
  • Pipeline by Eli Lilly and Company, H2 2016
  • Pipeline by F. Hoffmann-La Roche Ltd., H2 2016
  • Pipeline by Five Prime Therapeutics, Inc., H2 2016
  • Pipeline by Ignyta, Inc., H2 2016
  • Pipeline by Johnson & Johnson, H2 2016
  • Pipeline by Novartis AG, H2 2016
  • Pipeline by Pfizer Inc., H2 2016
  • Pipeline by Plexxikon Inc., H2 2016
  • Pipeline by SignalChem Lifesciences Corp, H2 2016
  • Pipeline by Transgene SA, H2 2016
  • Dormant Projects, H2 2016
  • Dormant Projects (Contd..1), H2 2016
  • Dormant Projects (Contd..2), H2 2016
  • Dormant Projects (Contd..3), H2 2016
  • Dormant Projects (Contd..4), H2 2016
  • Dormant Projects (Contd..5), H2 2016
  • Dormant Projects (Contd..6), H2 2016
  • Dormant Projects (Contd..7), H2 2016
  • Dormant Projects (Contd..8), H2 2016
  • Discontinued Products, H2 2016
  • Discontinued Products (Contd..1), H2 2016
  • Discontinued Products (Contd..2), H2 2016
  • Discontinued Products (Contd..3), H2 2016
  • Discontinued Products (Contd..4), H2 2016
  • Discontinued Products (Contd..5), H2 2016

List of Figures

  • Number of Products under Development for, H2 2016
  • Number of Products under Development by Therapy Area, H2 2016
  • Number of Products under Development by Top 10 Indication, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy/Combination Products, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
Back to Top